WO2011145211A1 - ケトレダクターゼ変異体 - Google Patents
ケトレダクターゼ変異体 Download PDFInfo
- Publication number
- WO2011145211A1 WO2011145211A1 PCT/JP2010/058631 JP2010058631W WO2011145211A1 WO 2011145211 A1 WO2011145211 A1 WO 2011145211A1 JP 2010058631 W JP2010058631 W JP 2010058631W WO 2011145211 A1 WO2011145211 A1 WO 2011145211A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- ketoreductase
- seq
- acid sequence
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/56—Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound to a condensed ring system having three or more carbocyclic rings, e.g. daunomycin, adriamycin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01184—Carbonyl reductase (NADPH) (1.1.1.184)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Definitions
- the present invention relates to a ketoreductase mutant used in a fermentation production method by microorganisms of a daunorubicin derivative produced semisynthetically.
- Anthracycline antibiotics are a group of compounds of aromatic polyketides, including aglycone part composed mainly of 7,8,9,10-tetrahydro-5,12-naphthacenequinone (below) and sugars mainly composed of amino sugars. It is a pigment glycoside (glycoside) composed of
- Anthracycline antibiotics bind to DNA and generate radicals to cleave DNA strands or inhibit topoisomerase II.
- Topoisomerase has DNase and ligase activity and catalyzes the temporary cleavage and recombination of DNA strands, but anthracycline antibiotics inhibit topoisomerase II, thereby impairing DNA replication and exhibiting antitumor activity.
- Anthracycline antibiotics are positioned as useful anticancer agents because they exhibit antitumor activity against a wide range of cancer cells, although accumulative cardiotoxic effects are observed.
- the main anthracycline anticancer agents currently used include those derived from fermented products such as daunorubicin and semi-synthetic products made from daunorubicin such as doxorubicin and epirubicin.
- Epirubicin is superior to daunorubicin and doxorubicin in terms of antitumor activity and toxicity, but the yield of the chemical synthesis process for reversing the 4-position hydroxyl group of the amino sugar moiety is low, and currently, epirubicin is the starting material for daunorubicin. Although it is produced, there are many problems in terms of manufacturing cost.
- ketoreductase epi-type ketoreductase
- the biosynthesis pathway of daunorubicin is altered and epithelial
- Non-patent Document 1 Since epidaunorubicin has the same conformation of the hydroxyl group of the amino sugar moiety as epirubicin, epidaunorubicin can be a very useful starting material in producing epirubicin.
- An object of the present invention is to provide a ketoreductase variant modified to improve the productivity of a daunorubicin derivative with respect to the ketoreductase used in the direct fermentation production method of a daunorubicin derivative such as epidaunorubicin by a microorganism. .
- ketoreductase used in the direct fermentation production method of a daunorubicin derivative by a microorganism
- the present inventors have intensively studied the modification of ketoreductase (EvaE) comprising the amino acid sequence described in SEQ ID NO: 1, and the 42nd and 149th positions.
- EtE ketoreductase
- the productivity of daunorubicin derivatives is improved by using a ketoreductase mutant in which at least one amino acid selected from the 153rd, 270th, and 306th amino acid groups is substituted with another amino acid.
- the present invention has been completed.
- the present invention provides a ketoreductase mutant that can be used for direct fermentation production of an efficient daunorubicin derivative by a microorganism and a polynucleotide (particularly DNA) encoding the mutant.
- the present invention also includes a step of providing a transformant with DNA encoding the ketoreductase mutant of the present invention, culturing the transformant, and collecting a daunorubicin derivative from the obtained culture medium.
- a method for producing a daunorubicin derivative is provided.
- the present invention provides a daunorubicin derivative produced by the transformant of the present invention.
- the present invention provides the following: (1) A mutant of a ketoreductase enzyme that can be used for the fermentation production of a daunomycin derivative, wherein the mutation is an insertion, substitution, or deletion of one or more amino acids in the amino acid sequence of the parent ketoreductase, or A ketoreductase variant that is an addition to one or both ends and improves the productivity of a daunomycin derivative as compared to the use of the parent ketoreductase. (2) The ketoreductase variant according to (1), wherein the parent ketoreductase comprises an amino acid sequence having 90% or more identity with the amino acid sequence of SEQ ID NO: 1.
- the ketoreductase variant according to (3) wherein the amino acid at the position corresponding to the 153rd amino acid in the amino acid sequence described in SEQ ID NO: 1 is substituted with an amino acid residue other than proline.
- the ketoreductase variant according to (3) wherein the amino acid at the position corresponding to the 270th amino acid in the amino acid sequence described in SEQ ID NO: 1 is substituted with arginine.
- (10) A polynucleotide encoding the ketoreductase variant according to any one of (1) to (9).
- (11) A transformant in which the DNA according to (10) is introduced into an actinomycete host originally having the ability to produce daunomycin and imparted with the ability to produce a daunomycin derivative.
- the transformant according to (11), wherein the actinomycete of the host is Streptomyces coeruleorubidus .
- (13) A method for producing a daunomycin derivative, comprising a step of culturing the transformant according to (12) and collecting the daunomycin derivative from the culture solution.
- (14) A daunomycin derivative obtained by the production method according to (13).
- the productivity of the daunorubicin derivative can be improved.
- the ketoreductase mutant of the present invention can be obtained as a result of mutating the parent ketoreductase. Further, in the present invention, this mutation is an insertion, substitution, or deletion of one or more amino acids, or addition to one or both ends in the amino acid sequence of ketoreductase, and This means that when the reductase mutant is used in a method for fermentative production of a daunorubicin derivative, the productivity of the daunorubicin derivative is improved as compared with the case where the parent ketoreductase is used.
- the parent ketoreductase is not limited as long as it can be used in the fermentation production method of a daunorubicin derivative, but ketoreductase consisting of the amino acid sequence shown in SEQ ID NO: 1 or a homologue thereof is preferable.
- the “homologue thereof” refers to an amino acid sequence represented by SEQ ID NO: 1 in which several amino acid insertions, substitutions or deletions, or additions to one or both ends thereof are made. And having at least 90% identity with the amino acid sequence represented by the formula (1) and retaining its ketoreductase activity.
- the parent ketoreductase when the parent ketoreductase consists of the amino acid sequence shown in SEQ ID NO: 1, it is selected from the group consisting of amino acids 42, 149, 153, 270, and 306 in the sequence Specific examples thereof include mutants in which one or two or more amino acid residues are substituted with other amino acid residues.
- the amino acid at position 42 is leucine
- the amino acid at position 149 is serine
- the amino acid at position 153 is amino acid other than proline
- the amino acid at position 270 is at arginine
- the amino acid at position 306 is asparagine.
- the thing substituted by the acid is mentioned as a preferable thing.
- the parent ketoreductase is a homologue of the amino acid sequence shown in SEQ ID NO: 1, it is selected from the group consisting of amino acids at positions corresponding to the 42nd, 149, 153, 270, and 306th amino acids. Specific examples thereof include those in which one or two or more amino acid residues are substituted with other amino acid residues.
- the position of the amino acid residue to be substituted in the homologue of the parent ketoreductase consisting of the amino acid sequence shown in SEQ ID NO: 1 can be easily selected by comparing amino acid sequences using a known algorithm.
- the position of the amino acid residue to be substituted can be specified by comparing the three-dimensional structure of the enzyme.
- a transformant producing a daunorubicin derivative can be obtained by introducing a DNA encoding the ketoreductase mutant of the present invention into an appropriate host originally having the ability to produce daunorubicin.
- a preferred host is actinomycetes, and known actinomycetes that produce daunorubicin are Streptomyces peuceticus and Streptomyces coeruleorubidus , which are ketoreductases of the present invention. It can be used as a host for introducing a DNA encoding a mutant.
- Baumomycin is a substance in which the amino sugar (L-daunosamine) portion of daunorubicin is modified, and daunorubicin is an intermediate of biosynthesis, so that actinomycetes that produce baumomycin can also be used as hosts.
- daunorubicin or baumycin-producing bacterium it is preferable to use a strain that has lost daunorubicin-producing ability as a host because it lacks the ketoreductase gene involved in the 4-position hydroxyl group biosynthesis of the L-daunosamine part of daunorubicin.
- the gene can be introduced into the host using conventional techniques such as mixing protoplasts with the target DNA, using phage, and using conjugative transfer. Can be implemented. In order to select a strain into which the gene has been introduced, it is desirable to introduce the target epitype ketoreductase gene together with a vector containing a selection marker gene.
- the selection marker gene is not limited as long as it can select a strain into which an epi-type ketoreductase gene has been introduced, but a kanamycin resistance gene, a streptomycin resistance gene, a hygromycin resistance gene, a biomycin resistance gene, an apramycin resistance gene, or the like is preferable.
- a promoter sequence that functions in the host to the epi type ketoreductase gene to be introduced, and an ermE * promoter derived from an erythromycin resistance gene [Schmitt-John, T. and Engels, JW] "Applied Microbiology and Biotechnology” (Germany), 1992, Vol. 36, p.493-498 (Non-Patent Document 4)], [Bibb MJ) et al., “Molecular Microbiology” (UK), 1994, Vol. 14, pp. 533-545 (Non-patent Document 5)].
- the presence state of the epi-type ketoreductase gene in the host may be incorporated into either a plasmid or a chromosome capable of self-replication outside the chromosome.
- the epi-type ketoreductase gene may be introduced by a method of replacing the host ketoreductase gene involved in the 4-position hydroxyl group biosynthesis of the L-daunosamine part of daunorubicin. Methods commonly used in actinomycetes can be used to replace genes [Practical Streptomyces Genetics], The John Innes Foundation ], (UK), Norwick, 2000, p. 311-338 (Non-Patent Document 6)].
- the daunorubicin derivative produced by the transformant of the present invention is a daunorubicin derivative in which the 4-position hydroxyl group of the L-daunosamine part of daunorubicin is inverted.
- Epidaunorubicin and epirubicin are preferable, and epidaunorubicin is more preferable.
- the transformant of the present invention can be cultured by a conventional method to produce a daunorubicin derivative.
- the medium conventional components such as glucose, sucrose, starch syrup, dextrin, starch, glycerol, molasses, animal / vegetable oil, etc. can be used as the carbon source.
- the nitrogen source soybean flour, wheat germ, corn steep liquor, cottonseed meal, meat extract, polypeptone, malto extract, yeast extract, ammonium sulfate, sodium nitrate, urea and the like can be used.
- sodium, potassium, calcium, magnesium, cobalt, chlorine, phosphoric acid (dipotassium hydrogen phosphate, etc.), sulfuric acid (magnesium sulfate, etc.) and other inorganic salts that can generate ions are added as necessary. Is also effective.
- various vitamins such as thiamine (thiamine hydrochloride, etc.), amino acids such as glutamic acid (sodium glutamate, etc.), asparagine (DL-asparagine, etc.), micronutrients such as nucleotides, antibiotics, etc. are added as necessary. You can also Furthermore, organic substances and inorganic substances that assist the growth of bacteria and promote the production of daunorubicin derivatives can be appropriately added.
- the pH of the medium is, for example, about pH 5.5 to pH 8.
- a culture method a solid culture method under aerobic conditions, a shaking culture method, an aeration and agitation culture method or a deep aerobic culture method can be used, and the deep aerobic culture method is particularly suitable.
- a suitable temperature for culturing is 15 ° C to 40 ° C, but in many cases grows at around 25 ° C to 35 ° C.
- the production of daunorubicin derivatives varies depending on the medium and culture conditions, or the host used, but in any culture method, the accumulation usually reaches its maximum in 2 to 10 days. When the amount of daunorubicin derivative in the culture reaches the maximum, the culture is stopped, and the target substance is isolated and purified from the culture.
- the usual separation means utilizing its properties for example, solvent extraction method, ion exchange resin method, adsorption or distribution column chromatography Extraction and purification can be carried out alone or in appropriate combination with a method, gel filtration method, dialysis method, precipitation method, crystallization method and the like.
- chromatography using an adsorbent such as silica gel or alumina, Sephadex LH-20 (Pharmacia), Toyopearl HW-40 (Tosoh) or the like may be performed. Examples of the present invention will be described below, but this is merely an example and is not intended to limit the present invention, and encompasses all of the many variations or modification means not exemplified here.
- Plasmid pIJ4070 containing ermE * promoter [Bibb, MJ et al., “Gene”, (UK), 1985 Year 38, p215-226 (Non-patent Document 7)] was double digested with Eco RI and Bam HI, fractionated by electrophoresis, and then an about 0.3 kbp Eco RI- Bam HI fragment containing the ermE * promoter was extracted from the gel. This DNA fragment was inserted into the Eco RI and Bam HI sites of plasmid pSET152 to obtain plasmid pSET152-E *.
- Chloro about Remo mycin-producing bacterium ketoreductase gene (Amycolatopsis orientalis) (evaE) is a Bam HI- Xba I fragment comprising the base sequence represented by SEQ ID NO: 2 and total synthesis, plasmid pSET152-E * of Bam HI and The plasmid pEVA-E was obtained by inserting into the Xba I site.
- primer pSET153-R (5'-GCGGATAACAATTTCACA-3 ', SEQ ID NO: 3) and pSETermE-R (5'- A random mutation was introduced by a combination of GTGCGGGCCTCTTCGCTATT-3 ′ and SEQ ID NO: 4).
- the evaE fragment mutation is double digested with Bam HI and Xba I, and a genomic DNA library cloned into the Bam HI and Xba I sites of pSET152-E *.
- Escherichia coli ET12567 / pUZ8002 strain that holds this genomic DNA library was added to 100 mL of LB liquid medium containing chloramphenicol, kanamycin, and apramycin at concentrations of 25 ⁇ g / mL, 25 ⁇ g / mL, and 50 ⁇ g / mL, respectively ( 1% diffcobact tryptone, 0.5% diffco yeast extract, 0.5% NaCl, 0.1% glucose) and cultured at 37 ° C. overnight to prepare a preculture solution.
- Patent Document 2 International Publication No. WO2009 / 035107 pamphlet
- MS agar medium 2% S soy flour, 2% mannitol, 2% agar
- spores were scraped off with 3 mL of 20% glycerin solution to prepare a host spore solution.
- the cells were collected by mixing 500 ⁇ L of the host spore solution and 500 ⁇ L of the E. coli solution prepared as described above, and then applied to an MS agar medium supplemented with MgCl 2 to a final concentration of 10 mmo1 / L. After culturing at 28 ° C. for 20 hours, 1 mL of sterile water containing 1 mg of apramycin and 1.5 mg of nalidixic acid was overlaid, and further cultured at 28 ° C. for 5 days to obtain an apramycin resistant strain.
- liquid production medium prepared in 8-minute test tubes [ Komiyama, T. et al., “The Journal of Antibiotics ], (Japan), 1977, Vol. 30, p.619-621 (Non-patent Document 8)] Inoculate 10 mL, incubate at 28 ° C for 2 days, and then prepare 1 mL of the culture solution in a 250 mL Erlenmeyer flask Was inoculated into 20 mL of the same liquid production medium and cultured with shaking at 32 ° C. for 7 days.
- Genomic DNA was prepared from the resulting highly productive clone using a MagExtractor genomic DNA extraction device (manufactured by Toyobo Co., Ltd.) according to the protocol, and primers pSET153-R (SEQ ID NO: 3) and pSETermE-R (SEQ ID NO: 4) were prepared. ) And PrimeSTAR-HS-DNA Polymerase (manufactured by Takara Bio Inc.) under the following cycle conditions (98 ° C., 10 seconds, 60 ° C., 5 seconds, 72 ° C., 1 minute ⁇ 25 times). As a result, an amplified DNA fragment of about 1 kbp was obtained.
- the amplified fragment was double-digested with Bam HI and Xba I, yielding plasmid pEVA-E-1 containing inserted into Bam HI and Xba I sites of plasmid pSET152-E * is amino acid substitution K153T evaE .
- PrimeSTAR HS DNA polymerase manufactured by TAKARA BIO INC.
- Random mutation introduction into K153T mutant gene Random mutation was introduced using the plasmid pEVA-E-1 described in Example 3 as a template and GeneMorph II Random Mutagenesis Kit (Stratagene) according to the attached manual.
- the evaE fragment mutation is double digested with Bam HI and Xba I, and a genomic DNA library cloned into the Bam HI and Xba I sites of pSET152-E *.
- primers pSET153-R SEQ ID NO: 3 and A125T-R (5′-ACGGTCGTCTCGGCTAGGCCGGGCG-3 ′, SEQ ID NO: 23), A125T-F (5′-GCCCGCGCCCGGCCTAGCCGAGACG-3 ′, SEQ ID NO: 24) And pSETermE-R (SEQ ID NO: 4) in each case using PrimeSTAR HS DNA polymerase (manufactured by Takara Bio Inc.) and carrying out a PCR reaction in the same manner as in Example 3. Two types of DNA solutions were obtained by purification using an application kit (Roche).
- PrimeSTAR HS DNA polymerase manufactured by Takara Bio Inc.
- primers pSET153-R SEQ ID NO: 3
- pSETermE-R SEQ ID NO: 4
- PCR was carried out in the same manner as in example 3, the amplified fragment was double-digested with Bam HI and Xba I, and inserted into the Bam HI and Xba I sites of plasmid pSET152-E * Q42L and K153T and C270R and E306D Plasmid pEVA-E-5 containing evaE with the amino acid substitution was obtained.
- ketoreductase mutant of the present invention can be used for the production of daunorubicin derivatives.
- this invention was demonstrated along the specific aspect, the deformation
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
(1)ダウノマイシン誘導体の発酵生産に使用可能なケトレダクターゼ酵素の変異体であって、親ケトレダクターゼのアミノ酸配列において、変異が1個または複数個のアミノ酸の挿入、置換、または欠失、若しくはその一方または両末端への付加であり、親ケトレダクターゼを使用したときよりもダウノマイシン誘導体の生産性が向上するケトレダクターゼ変異体。
(2)親ケトレダクターゼが配列番号1のアミノ酸配列と90%以上の同一性を有するアミノ酸配列を含むことを特徴とする(1)に記載のケトレダクターゼ変異体。
(3)配列番号1記載のアミノ酸配列中の42、149、153、270および306番目のアミノ酸に相当する位置のアミノ酸からなる群から選択される1個または2個以上のアミノ酸残基が、他のアミノ酸残基により置換されてなる、(2)に記載のケトレダクターゼ変異体。
(4)配列番号1記載のアミノ酸配列中の42番目のアミノ酸に相当する位置のアミノ酸がロイシンに置換されていることを特徴とする(3)に記載のケトレダクターゼ変異体。
(5)配列番号1記載のアミノ酸配列中の149番目のアミノ酸に相当する位置のアミノ酸がセリンに置換されていることを特徴とする(3)に記載のケトレダクターゼ変異体。
(6)配列番号1記載のアミノ酸配列中の153番目のアミノ酸に相当する位置のアミノ酸がプロリン以外のアミノ酸残基に置換されていることを特徴とする(3)に記載のケトレダクターゼ変異体。
(7)配列番号1記載のアミノ酸配列中の270番目のアミノ酸に相当する位置のアミノ酸がアルギニンに置換されていることを特徴とする(3)に記載のケトレダクターゼ変異体。
(8)配列番号1記載のアミノ酸配列中の306番目のアミノ酸に相当する位置のアミノ酸がアスパラギン酸に置換されていることを特徴とする(3)に記載のケトレダクターゼ変異体。
(9)ダウノマイシン誘導体がエピダウノマイシンであることを特徴とする(1)~(8)の何れか一項に記載のケトレダクターゼ変異体。
(10)(1)~(9)の何れか一項に記載のケトレダクターゼ変異体をコードするポリヌクレオチド。
(11)(10)に記載のDNAが本来ダウノマイシンを生産する能力を有した放線菌宿主に導入され、ダウノマイシン誘導体生産能が付与された形質転換体。
(12)宿主の放線菌がStreptomyces coeruleorubidusであることを特徴とする(11)に記載の形質転換体。
(13)(12)に記載の形質転換体を培養して、培養液からダウノマイシン誘導体を採取する工程を含んでなるダウノマイシン誘導体の製造方法。
(14)(13)に記載の製造方法で得られるダウノマイシン誘導体。
以下に本発明の実施例を示すが、これは単なる一例であって本発明を限定するものではなく、ここに例示しなかった多くの変法あるいは修飾手段のすべてを包括するものである。
ermE*プロモーターを含むプラスミドpIJ4070[ビブ(Bibb,M.J.)ら著,「ジーン(Gene)」,(英国),1985年,第38巻,p215-226(非特許文献7)]をEcoRI及びBamHIで二重消化し、電気泳動により分画後、ermE*プロモーターを含む約0.3kbpのEcoRI-BamHI断片をゲルより抽出した。このDNA断片をプラスミドpSET152のEcoRI及びBamHI部位に挿入しプラスミドpSET152-E*を得た。
実施例1で作成したプラスミドpEVA-Eを鋳型とし、以下のプライマーセットでPrimeSTAR HS DNAポリメラーゼ(タカラバイオ株式会社製)を使用して(98℃・10秒、68℃・7分)×25回のサイクルによるPCR反応を行なった。プライマー塩基配列の大文字の箇所は、サチュレーション変異の導入部分を示す。
[1] NAC-F
5’-gcggaacagatcctcaagNACgccacggcaaatggccag-3’(配列番号5)
NAC-R
5’-ctggccatttgccgtggcGTNcttgaggatctgttccgc-3’(配列番号6)
[2] NCC-F
5’-gcggaacagatcctcaagNCCgccacggcaaatggccag-3’(配列番号7)
NCC-R
5’-ctggccatttgccgtggcGGNcttgaggatctgttccgc-3’(配列番号8)
[3] NGC-F
5’-gcggaacagatcctcaagNGCgccacggcaaatggccag-3’(配列番号9)
NGC-R
5’-ctggccatttgccgtggcGCNcttgaggatctgttccgc-3’(配列番号10)
[4] NTC-F
5’-gcggaacagatcctcaagNTCgccacggcaaatggccag-3’(配列番号11)
NTC-R
5’-ctggccatttgccgtggcGANcttgaggatctgttccgc-3’(配列番号12)
[5] VAG-F
5’-gcggaacagatcctcaagVAGgccacggcaaatggccag-3’(配列番号13)
VAG-R
5’-ctggccatttgccgtggcCTBcttgaggatctgttccgc-3’(配列番号14)
[6] TGG-F
5’-gcggaacagatcctcaagTGGgccacggcaaatggccag-3’(配列番号15)
TGG-R
5’-ctggccatttgccgtggcCCActtgaggatctgttccgc-3’(配列番号16)
[7] ATG-F
5’-gcggaacagatcctcaagATGgccacggcaaatggccag-3’(配列番号17)
ATG-R
5’-ctggccatttgccgtggcCATcttgaggatctgttccgc-3’(配列番号18)
実施例1で単離した最も生産性の高かったK153Tのアミノ酸置換を有するクローン株のゲノムDNAからプライマーpSET153-R(配列番号3)とpSETermE-R(配列番号4)の組合せでPrimeSTAR HS DNAポリメラーゼ(タカラバイオ株式会社製)を使用してPCR反応を以下のサイクル条件で行った(98℃・10秒、60℃・5秒、72℃・1分)×25回。その結果、約1kbpの増幅断片を得た。増幅された断片をBamHI及びXbaIで二重消化し、プラスミドpSET152-E*のBamHI及びXbaI部位に挿入してK153Tのアミノ酸置換されたevaEを含むプラスミドpEVA-E-1を得た。このプラスミドpEVA-E-1からプライマーpSET153-R(配列番号3)とQ149S-R(5’-TTCCGCTGTCAGCTTCTG-3'、配列番号19)、Q149S-F(5’-TCGATCCTCAAGACGGCCACGGC-3'、配列番号20)とpSETermE-R(配列番号4)の組合せでそれぞれPrimeSTAR HS DNAポリメラーゼ(タカラバイオ株式会社製)を使用して上述のようにPCR反応を行い、このPCR反応産物をハイピュアーPCRプロダクトピュリフィケーションキット(ロッシュ社製)を用いて精製し、2種類のDNA溶液を得た。この2種類のDNA溶液をT4ポリヌクレオチドキナーゼ(日本ジーン社製)を用いてリン酸化した後、プラスミドpSET152-E*のBamHI及びXbaI部位に挿入してQ149S(149番目のグルタミンがセリンに置換)とK153Tのアミノ酸置換されたevaEを含むプラスミドpEVA-E-2を得た。
実施例3記載のプラスミドpEVA-E-1を鋳型としGeneMorph II Random Mutagenesis Kit(ストラタジーン社製)を用い添付マニュアルに従い、ランダム変異を導入した。
実施例4で単離したevaE-3のゲノムDNAからプライマーpSET153-R(配列番号3)とT808C-R(5’-GTTCCACACGGGTCACCTCG-3'、配列番号21)、T808C-F(5’-CGAGGTGACCCGTGTGGAAC-3'、配列番号22)とpSETermE-R(配列番号4)の組合せでそれぞれPrimeSTAR HS DNAポリメラーゼ(タカラバイオ株式会社製)を使用して実施例3と同様にPCR反応を行い、このPCR反応産物をハイピュアーPCRプロダクトピュリフィケーションキット(ロッシュ社製)を用いて精製し、2種類のDNA溶液を得た。この2種類のDNA溶液を混合したものをテンプレートとして、プライマーpSET153-R(配列番号3)とpSETermE-R(配列番号4)の組合せでPrimeSTAR HS DNAポリメラーゼ(タカラバイオ株式会社製)を使用して実施例3と同様にPCR反応を行い、増幅された断片をBamHI及びXbaIで二重消化し、プラスミドpSET152-E*のBamHI及びXbaI部位に挿入してK153TとC270RとE306Dのアミノ酸置換されたevaEを含むプラスミドpEVA-E-4を得た。
以上、本発明を特定の態様に沿って説明したが、当業者に自明の変形や改良は本発明の範囲に含まれる。
配列番号2~24の各配列で表される塩基配列は、合成DNAである。配列番号5~12の記号「n」は、それぞれ、任意の塩基を表す。
Claims (14)
- ダウノマイシン誘導体の発酵生産に使用可能なケトレダクターゼ酵素の変異体であって、親ケトレダクターゼのアミノ酸配列において、変異が1個または複数個のアミノ酸の挿入、置換、または欠失、若しくはその一方または両末端への付加であり、親ケトレダクターゼを使用したときよりもダウノマイシン誘導体の生産性が向上するケトレダクターゼ変異体。
- 親ケトレダクターゼが配列番号1で表されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を含むことを特徴とする、請求項1に記載のケトレダクターゼ変異体。
- 配列番号1で表されるアミノ酸配列中の42、149、153、270および306番目のアミノ酸に相当する位置のアミノ酸からなる群から選択される1個または2個以上のアミノ酸残基が、他のアミノ酸残基により置換されてなる、請求項2に記載のケトレダクターゼ変異体。
- 配列番号1で表されるアミノ酸配列中の42番目のアミノ酸に相当する位置のアミノ酸がロイシンに置換されている、請求項3に記載のケトレダクターゼ変異体。
- 配列番号1で表されるアミノ酸配列中の149番目のアミノ酸に相当する位置のアミノ酸がセリンに置換されている、請求項3に記載のケトレダクターゼ変異体。
- 配列番号1で表されるアミノ酸配列中の153番目のアミノ酸に相当する位置のアミノ酸がプロリン以外のアミノ酸残基に置換されている、請求項3に記載のケトレダクターゼ変異体。
- 配列番号1で表されるアミノ酸配列中の270番目のアミノ酸に相当する位置のアミノ酸がアルギニンに置換されている、請求項3に記載のケトレダクターゼ変異体。
- 配列番号1で表されるアミノ酸配列中の306番目のアミノ酸に相当する位置のアミノ酸がアスパラギン酸に置換されている、請求項3に記載のケトレダクターゼ変異体。
- ダウノマイシン誘導体がエピダウノマイシンである、請求項1~8のいずれか一項に記載のケトレダクターゼ変異体。
- 請求項1~9のいずれか一項に記載のケトレダクターゼ変異体をコードするポリヌクレオチド。
- 請求項10に記載のポリヌクレオチドが本来ダウノマイシンを生産する能力を有した放線菌宿主に導入され、ダウノマイシン誘導体生産能が付与された形質転換体。
- 宿主の放線菌がStreptomyces coeruleorubidusである、請求項11に記載の形質転換体。
- 請求項12に記載の形質転換体を培養して、培養液からダウノマイシン誘導体を採取する工程を含んでなるダウノマイシン誘導体の製造方法。
- 請求項13に記載の製造方法で得られるダウノマイシン誘導体。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/699,206 US8697409B2 (en) | 2010-05-21 | 2010-05-21 | Ketoreductase mutant |
PCT/JP2010/058631 WO2011145211A1 (ja) | 2010-05-21 | 2010-05-21 | ケトレダクターゼ変異体 |
EP10851775.6A EP2573174B1 (en) | 2010-05-21 | 2010-05-21 | Ketoreductase mutant |
CN201080066932.6A CN102906258B (zh) | 2010-05-21 | 2010-05-21 | 酮还原酶突变体 |
KR1020127032062A KR101718985B1 (ko) | 2010-05-21 | 2010-05-21 | 케토리덕타아제 변이체 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2010/058631 WO2011145211A1 (ja) | 2010-05-21 | 2010-05-21 | ケトレダクターゼ変異体 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011145211A1 true WO2011145211A1 (ja) | 2011-11-24 |
Family
ID=44991335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/058631 WO2011145211A1 (ja) | 2010-05-21 | 2010-05-21 | ケトレダクターゼ変異体 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8697409B2 (ja) |
EP (1) | EP2573174B1 (ja) |
KR (1) | KR101718985B1 (ja) |
CN (1) | CN102906258B (ja) |
WO (1) | WO2011145211A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016159092A1 (ja) * | 2015-03-30 | 2016-10-06 | Meiji Seikaファルマ株式会社 | エピルビシンの製造方法およびその新規な製造中間体 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108048416B (zh) * | 2017-12-25 | 2021-05-18 | 吉林凯莱英医药化学有限公司 | 改进的酮还原酶突变体及其制备方法和应用 |
CN108048417B (zh) * | 2018-01-22 | 2020-10-30 | 吉林凯莱英医药化学有限公司 | 酮还原酶突变体及其应用 |
CN110257351B (zh) * | 2019-06-13 | 2021-04-27 | 凯莱英医药集团(天津)股份有限公司 | 酮还原酶突变体及生产手性醇的方法 |
CN111593077B (zh) * | 2019-12-30 | 2021-10-01 | 南京朗恩生物科技有限公司 | 一种生物催化制备(r)-4-氯-3-羟基丁酸乙酯的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006111561A1 (en) | 2005-04-21 | 2006-10-26 | Dsm Ip Assets B.V. | Improved microbial production of anthracyclins |
JP2007502124A (ja) * | 2003-08-11 | 2007-02-08 | コデクシス, インコーポレイテッド | 改良ケトレダクターゼポリペプチドおよび関連ポリヌクレオチド |
WO2009035107A1 (ja) | 2007-09-14 | 2009-03-19 | Meiji Seika Kaisha, Ltd. | 非天然型抗生物質の製造方法 |
-
2010
- 2010-05-21 CN CN201080066932.6A patent/CN102906258B/zh active Active
- 2010-05-21 KR KR1020127032062A patent/KR101718985B1/ko active IP Right Grant
- 2010-05-21 WO PCT/JP2010/058631 patent/WO2011145211A1/ja active Application Filing
- 2010-05-21 EP EP10851775.6A patent/EP2573174B1/en active Active
- 2010-05-21 US US13/699,206 patent/US8697409B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007502124A (ja) * | 2003-08-11 | 2007-02-08 | コデクシス, インコーポレイテッド | 改良ケトレダクターゼポリペプチドおよび関連ポリヌクレオチド |
WO2006111561A1 (en) | 2005-04-21 | 2006-10-26 | Dsm Ip Assets B.V. | Improved microbial production of anthracyclins |
WO2009035107A1 (ja) | 2007-09-14 | 2009-03-19 | Meiji Seika Kaisha, Ltd. | 非天然型抗生物質の製造方法 |
Non-Patent Citations (14)
Title |
---|
"Practical Streptomyces Genetics", 2000, THE JOHN INNES FOUNDATION, pages: 311 - 338 |
BIBB, M. J. ET AL., MOLECULAR MICROBIOLOGY, (UNITED KINGDOM, vol. 14, 1994, pages 533 - 545 |
BIBB, M.J. ET AL., GENE, (UNITED KINGDOM, vol. 38, 1985, pages 215 - 226 |
BIBB, M.J. ET AL., MOLECULAR MICROBIOLOGY, (UNITED KINGDOM, vol. 14, 1994, pages 533 - 545 |
KOMIYAMA, T. ET AL., THE JOURNAL OF ANTIBIOTICS, (JAPAN, vol. 30, 1977, pages 619 - 621 |
LIPMAN DJ; PEARSON WR, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (U.S.A., vol. 85, 1988, pages 2444 - 2448 |
LIPMAN DJ; PEARSON WR, SCIENCE, (U.S.A., vol. 227, 1985, pages 1435 - 1441 |
MADDURI K ET AL.: "Production of the antitumor drug epirubicin (4'-epidoxorubicin) and its precursor by a genetically engineered strain of Streptomyces peucetius.", NAT BIOTECHNOL., vol. 16, no. 1, 1998, pages 69 - 74, XP002210929 * |
MADDURI, K. ET AL., NATURE BIOTECHNOLOGY, (U.S.A., vol. 16, 1998, pages 69 - 74 |
PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 2444 - 2448 |
SCHMITT-JOHN, T.; ENGELS, J. W., APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, (GERMANY, vol. 36, 1992, pages 493 - 498 |
SCHMITT-JOHN, T.; ENGELS, J.W., APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, (GERMANY, vol. 36, 1992, pages 493 - 498 |
SCIENCE, vol. 227, 1985, pages 1435 - 1441 |
SHANG KE ET AL.: "Production of 4'- epidaunorubicin by metabolic engineering of Streptomyces coeruleorubidus strain SIPI-1482.", WORLD J MICROBIOL BIOTECHNOL., vol. 24, no. 7, 2008, pages 1107 - 1113, XP019617033 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016159092A1 (ja) * | 2015-03-30 | 2016-10-06 | Meiji Seikaファルマ株式会社 | エピルビシンの製造方法およびその新規な製造中間体 |
JPWO2016159092A1 (ja) * | 2015-03-30 | 2018-01-25 | Meiji Seikaファルマ株式会社 | エピルビシンの製造方法およびその新規な製造中間体 |
CN107683284A (zh) * | 2015-03-30 | 2018-02-09 | 明治制果药业株式会社 | 表柔比星的制造方法及其新的制造中间体 |
US10301343B2 (en) | 2015-03-30 | 2019-05-28 | Meiji Seika Pharma Co., Ltd. | Method of producing epirubicin and novel production intermediate thereof |
Also Published As
Publication number | Publication date |
---|---|
CN102906258B (zh) | 2015-06-17 |
CN102906258A (zh) | 2013-01-30 |
US20130116416A1 (en) | 2013-05-09 |
EP2573174A1 (en) | 2013-03-27 |
EP2573174B1 (en) | 2017-01-25 |
KR20130090774A (ko) | 2013-08-14 |
US8697409B2 (en) | 2014-04-15 |
KR101718985B1 (ko) | 2017-03-22 |
EP2573174A4 (en) | 2013-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8664186B2 (en) | Stambomycin and derivatives, their production and their uses as drugs | |
KR101272454B1 (ko) | 새로운 카나마이신 화합물, 카나마이신 생산 스트렙토마이세스 속 미생물 및 카나마이신의 생산 방법 | |
US8778654B2 (en) | Recombinant bacteria for producing deoxyviolacein and uses thereof | |
JP5422387B2 (ja) | 非天然型抗生物質の製造方法 | |
WO2011145211A1 (ja) | ケトレダクターゼ変異体 | |
Yang et al. | Nucleotidylation of unsaturated carbasugar in validamycin biosynthesis | |
Yu et al. | Oxytetracycline biosynthesis improvement in Streptomyces rimosus following duplication of minimal PKS genes | |
WO2006111561A1 (en) | Improved microbial production of anthracyclins | |
JP5601788B2 (ja) | ケトレダクターゼ変異体 | |
JPH05506570A (ja) | コバラミンおよび/またはコバミドの生合成に関係するポリペプチド、それらのポリペプチドをコードするdna配列、調製方法およびそれらの使用 | |
Lamichhane et al. | Heterologous production of spectinomycin in Streptomyces venezuelae by exploiting the dTDP-D-desosamine pathway | |
KR100679759B1 (ko) | 관능기에 의해 수식된 이차 대사산물을 생산하는형질전환체 및 신규 생합성 유전자 | |
Thuy et al. | Expression of 2-deoxy-scyllo-inosose synthase (kan A) from kanamycin gene cluster in Streptomyces lividans | |
JP4633519B2 (ja) | ミデカマイシン高生産菌 | |
Jong-Seog et al. | Hydroxylation of indole by PikC cytochrome P450 from Streptomyces venezuelae and engineering its catalytic activity by site-directed mutagenesis | |
Lei et al. | In vivo investigation of the substrate recognition capability and activity affecting amino acid residues of glycosyltransferase FscMI in the biosynthesis of candicidin | |
WO2009008664A2 (en) | A producing method for gentamicin a2 or the precursors and recombinant microorganisms producing the same | |
Voitsekhovskaia et al. | Baikalomycins AC, New Aquayamycin-Type Angucyclines Isolated from Lake Baikal Derived sp. IB201691-2A. | |
Feng et al. | Biosynthesis of 2′-O-methylmyxalamide D in the myxobacterium Cystobacter fuscus: a polyketide synthase-nonribosomal peptide synthetase system for the myxalamide D skeleton and a methyltransferase for the final O-methylation | |
Pageni et al. | Characterization of a chalcosyltransferase (gerGTII) in dihydrochalcomycin biosynthesis | |
Salem | Biosynthesis of marineosin, a spiroaminal undecylprodiginine natural product | |
Kallio | Type II aromatic polyketide biosynthetic tailoring enzymes: diversity and adaptation in Streptomyces secondary metabolism. | |
Shepherd | Combinatorial Biosynthetic Derivatization of the Antitumoral Agent Gilvocarcin V | |
WO2001023578A1 (en) | The gene cluster involved in aclacinomycin biosynthesis, and its use for genetic engineering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080066932.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10851775 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13699206 Country of ref document: US Ref document number: 3614/KOLNP/2012 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2010851775 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010851775 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20127032062 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: JP |